Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）

NSCLC Clinical Trial

Official title:

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05465343
• Other study ID #: NCC3050
• Status: Recruiting
• Phase: Phase 2
• Start date: July 11, 2022
• Est. completion date: June 30, 2023

Study information

• Verified date: July 2022
• Source: Peking Union Medical College
• Contact: Junling Li, Professor
• Phone: 010-87788495
• Email: lijunling[@]cicams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a a single-arm, single-center, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: June 30, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or Female aged =18 years old;

2. ECOG PS 0-2;

3. Histologically or cytopathologically confirmed non-small cell lung cancer (NSCLC) ; Tumor tissue samples or blood samples are confirmed to be EGFR mutations (including 19del or 21L858R or T790M);

4. Patients with brain metastases treatment-naïve, or treated with EGFR TKI intracranial progression alone without significant associated symptoms, or intolerance to EGFR TKI treatment(including Gefitinib, Erlotinib, Icotinib, Afatinib, Dacomitinib, Osimertinib, Almonertinib), or intracranial progression after brain radiotherapy;

5. Life expectancy >3 months;

6. Subjects with asymptomatic meningeal metastases can be enrolled, prior corticosteroid use allowed; Subjects requiring corticosteroids during the study are excluded;

7. According to RECIST1.1, the subject has at least 1 intracranial measurable lesion;

8. Adequate organ function (28 days before enrollment), including:

1)Blood routine examination HB=90 g/L(No blood transfusion within 14 days prior to enrollment) ANC=1.5×109 /L PLT=100×109 /L 2)Biochemical examination TBIL=1.5 times ULN AST and ALT=2.5 times ULN (with liver metastasis, AST and ALT=5 times ULN) Cr=1×ULN,CrCL =50 mL /min (according to Cockcroft-Gault formula) PT/INR=1.5 times ULN; aPTT=1.5 times ULN (If the subject is receiving anticoagulation, PT or aPTT is within the therapeutic range expected for anticoagulant use) 9.No systemic corticosteroid therapy within 4 weeks prior to treatment; 10.Males of reproductive potential or females of potential pregnancy must take effective contraceptive measures (eg, oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicide) during the study and and within 12 months after drug discontinuation; 11.Being able to understand and voluntarily participate in the study, and sign the informed consent form, with good compliance and for follow-up.

Exclusion Criteria:

1.Male or Female aged =18 years old; 2.ECOG PS 0-2; 3.Histologically or cytopathologically confirmed non-small cell lung cancer (NSCLC) ; Tumor tissue samples or blood samples are confirmed to be EGFR mutations (including 19del or 21L858R or T790M); 4.Patients with brain metastases treatment-naïve, or treated with EGFR TKI intracranial progression alone without significant associated symptoms, or intolerance to EGFR TKI treatment(including Gefitinib, Erlotinib, Icotinib, Afatinib, Dacomitinib, Osimertinib, Almonertinib), or intracranial progression after brain radiotherapy; 5.Life expectancy >3 months; 6.Subjects with asymptomatic meningeal metastases can be enrolled, prior corticosteroid use allowed; Subjects requiring corticosteroids during the study are excluded; 7.According to RECIST1.1, the subject has at least 1 intracranial measurable lesion; 8.Adequate organ function (28 days before enrollment), including:

1. Blood routine examination HB=90 g/L(No blood transfusion within 14 days prior to enrollment) ANC=1.5×109 /L PLT=100×109 /L

2. Biochemical examination TBIL=1.5 times ULN AST and ALT=2.5 times ULN (with liver metastasis, AST and ALT=5 times ULN) Cr=1×ULN,CrCL =50 mL /min (according to Cockcroft-Gault formula) PT/INR=1.5 times ULN; aPTT=1.5 times ULN (If the subject is receiving anticoagulation, PT or aPTT is within the therapeutic range expected for anticoagulant use) 9.No systemic corticosteroid therapy within 4 weeks prior to treatment; 10.Males of reproductive potential or females of potential pregnancy must take effective contraceptive measures (eg, oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicide) during the study and and within 12 months after drug discontinuation; 11.Being able to understand and voluntarily participate in the study, and sign the informed consent form, with good compliance and for follow-up.

Exclusion Criteria:

1.Known or suspected allergy to Furmonertinib or other components; 2.With EGFR Ex20ins mutation; 3.Treated more than one EGFR-TKI (excluding Patients with T790M mutation use Osimertinib or Almonertinib only intracranial progression after prior first/second generation EGFR-TKI resistance ) , chemotherapy more than one line (excluding change of medication due to adverse events or maintenance treatment); 4.Subjects who have received other anti-tumor therapy within four weeks prior to the first dose of the study or who have failed to recover (= grade 1) from an adverse event resulting from prior treatment; 5.Any of the following cardiac criteria:

1. QTc>470 ms on ECG at resting state, when the first abnormality occurs, the test is repeated 2 times within 48h, and the average result of 3 times is calculated.

2. Various clinically significant abnormalities in rhythm, conduction, and resting ECG patterns, such as complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, PR interval >250msec, etc.

3. Factors that may increase the risk of QTc prolongation or the risk of arrhythmic events.

6.Pregnant or breastfeeding women; 7.Known hepatitis C virus (positive HCV Ab) or human immunodeficiency virus (positive HIV antibody) infection, positive HBsAg or HBCAb with positive HBV DNA copy number (>500 IU/ml); 8.Previous interstitial lung disease (ILD); 9.Having severe or uncontrolled systemic disease, including active opportunistic infection or progressive (severe) infection, uncontrolled diabetes, cardiovascular disease (III or IV heart failure by NYHA Functional Classification, second degree or greater atrioventricular block, myocardial infarction or unstable arrhythmia or unstable angina within the past 6 months, cerebral infarction within 3 months, etc.), pulmonary disease (interstitial pneumonia, obstructive pulmonary disease and history of symptomatic bronchospasm); 10.Meningeal metastases with CNS symptoms may be enrolled if the subject's intracranial metastases can be adequately treated and CNS symptoms can be restored to a level less than or equal to CTCAE1 and remain stable prior to enrollment; 11.Received a live vaccination within 4 weeks prior to the start of study treatment; 12.Major surgery (excluding diagnostic surgery) within 4 weeks prior to the start of treatment; 13.Known history of mental disease or drug abuse, and currently having an attack or still taking drugs; 14.Serious gastrointestinal dysfunction, or disease that may affect the intake, transportation or absorption of investigational product; 15.History of other malignant tumors within 3 years, except for cured basal cell carcinoma and cervical carcinoma in situ; 16.According to the investigators, subjects with other serious acute or chronic disease, mental disease , laboratory abnormalities that may increase the risk or interfere with the interpretation of study results are excluded; 17.Subjects who are or have been involved in other clinical studies within 4 weeks; 18.According to the investigator, subjects may not complete this study or may not comply with the requirements of this study.

Related Conditions & MeSH terms

• Brain Metastases
• Brain Neoplasms
• EGFR-mutation
• Neoplasm Metastasis
• NSCLC

Intervention

Drug:
• Furmonertinib
Furmonertinib 160mg orally QD

Locations

Country	Name	City	State
China	Ethics Committee	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intracranial Objective Response Rate (iORR)	Proportion of subjects whose intracranial tumors were assessed as complete response(CR) or partial response(PR) according to RECIST 1.1.	Approximately 12 weeks after the first patient begin study treatment
Primary	Intracranial Progression Free Survival (iPFS)	The time from the first does of the study drugs to the intracranial progression of the disease or death for any reason.	Approximately 18 months after the first patient begin study treatment
Secondary	Objective Response Rate (ORR)	Proportion of subjects whose tumors were assessed as complete response(CR) or partial response(PR) according to RECIST 1.1.	Approximately 12 weeks following the first dose of study drug
Secondary	Disease Control Rate (DCR)	Proportion of subjects whose tumors were assessed as CR, PR or stable disease (SD) according to RECIST 1.1.	Approximately 18 months from the first patient begin study treatment
Secondary	Disease progression free survival (PFS)	The time from the first does of the study drugs to the progression of the disease or death for any reason.	Approximately 18 months after the first patient begin study treatment
Secondary	Overall survival (OS)	The time from the first does of the study drugs to the death for any reason.	Approximately 24 months after the first patient begin study treatment
Secondary	Duration of Response (DOR)	The time from objective tumor remission (CR or PR) to the progression of the disease or death for any reason.	Approximately 18 months after the first patient begin study treatment
Secondary	Adverse Events (AEs)	The number of patients with adverse events and the severity according to CTCAE v5.0	From the start of study drug to 28 days after the last dose of study drug